Dabigatran etexilate is the first commercially available oral direct thrombin inhibitor. A single
trial has studied patients at risk for stroke associated with nonvalvular atrial fibrillation; in this …

Dabigatran etexilate (dabigatran) is a novel, oral, reversible, direct thrombin inhibitor that
exhibits several advantages over warfarin for therapeutic anticoagulation. The predictable …

For more than 5 decades, warfarin has been the mainstay of therapy when oral
anticoagulation is required. It has been shown to be effective in the prevention as well as …

Atrial fibrillation (AF) affects more than 3 million Americans and is expected to reach
epidemic proportions as the US population ages. The presence of AF increases lifetime …

BACKGROUND: Stroke and systemic thromboembolism remain critical causes of mortality
and morbidity in patients with paroxysmal or persistent atrial fibrillation. Dabigatran etexilate …

Dabigatran, an oral direct thrombin inhibitor, was the first of a new class of drugs referred to
as non-vitamin K oral anticoagulants. Dabigatran is better than warfarin for stroke prevention …

Atrial fibrillation (AF) is well known as one of the leading causes of stroke and systemic
embolism. Anticoagulation therapy is recommended in all patients at moderate-to-high risk …

Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous
thromboembolism after knee and hip replacement, the prevention of stroke and systemic …

Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial
fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of …

Background Dabigatran is a direct thrombin inhibitor and an anticoagulant that is prescribed
to prevent ischemic stroke and systemic embolism in non-valvular atrial fibrillation …